J Nutr Biochem 62:143154 Zhang N, Tao J, Gao L, Bi Y, Li P, Wang H, Zhu D, Feng W (2020) Liraglutide attenuates nonalcoholic fatty liver disease by modulating gut microbiota in rats administered a high-fat diet
doi: 10.1038/sj.embor.7400731 4 GillSRPopMDeboyRTEckburgPBTurnbaughPJSamuelBSet al
Key Features Research Use Only (RUO) compound 5 mg per vial lyophilized powder format for convenient handling in laboratory settings Manufactured and packaged for research applications Product Specifications Compound Name: BPC-157 Form: Lyophilized Powder Total Quantity: 5 mg per Vial Grade: Research Use Only (RUO) Intended Use This product is intended solely for laboratory research and investigational purposes
But because these changes directly affect how your digestive system functions, they can also lead to side effects, especially during the first few weeks as your body adjusts
During GLP-1 treatment , contact your GP if you experience: Severe or persistent abdominal pain , particularly if different in character from your usual IBS symptoms or if radiating to your back (which may indicate pancreatitisstop the medication and seek urgent medical attention) Significant worsening of diarrhoea or constipation that doesn't improve with standard measures Persistent nausea or vomiting affecting your ability to maintain adequate nutrition and hydration New symptoms such as rectal bleeding, unintentional weight loss (beyond expected therapeutic effect), or nocturnal symptoms waking you from sleep Difficulty distinguishing between IBS symptoms and medication side effects Sudden pain in the upper right abdomen, fever, or yellowing of the skin/eyes (possible gallbladder diseaseseek urgent medical attention) Red flag symptoms requiring urgent medical attention include: Severe, unremitting abdominal pain Rectal bleeding or black, tarry stools Unexplained weight loss Persistent vomiting with inability to keep fluids down Signs of dehydration Your GP may arrange appropriate investigations such as blood tests (full blood count, inflammatory markers, coeliac serology) or faecal calprotectin testing to distinguish IBS from inflammatory bowel disease where appropriate
UV rays are well-known for their detrimental effects on skin health and their association with the development of skin cancers
